Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 and Cetuximab in Resectable Pancreatic Cancer
NCT02241187Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2014
- Primary completion
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegvorhyaluronidase alfa in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Effects of PEGPH20 on tumors at 1 year. Started Sep 2014; status: completed.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02241187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241187.